mmaf

MMAF (MonoMethyl auristatin F), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin.

MMAF-OMe (Monomethyl auristatin F methyl ester) is an antitubulin agent which inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively. MMAF-Ome is also an ADC cytotoxin.

MMAF Hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF Hydrochloride is an effective tubulin polymerization inhibitor and is used as an antitumor compound.

MMAF sodium is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF sodium is an effective tubulin polymerization inhibitor and is used as an antitumor agent.

MAL-di-EG-Val-Cit-PAB-MMAF is a chemical compound consisting of the linker (MAL-di-EG-Val-Cit-PAB) and the potent tubulin polymerization inhibitor (MMAF, Monomethyl auristatin F) [1].

MC-Alkyl-Hydrazine Modified MMAF is a potent antitumor drug-linker conjugate for ADC, utilizing Modified MMAF, a tubulin inhibitor, connected via a noncleavable MC-Alkyl-Hydrazine linkage[1].

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

PEG4-aminooxy-MMAF is a drug-linker conjugate designed for antibody-drug conjugates (ADC) that exhibits potent antitumor activity. It incorporates MMAF, a powerful antitubulin agent, connected through a non-cleavable PEG4 linker[1].

Modified MMAF-C5-COOH is a drug-linker conjugate for ADC.

DBM-MMAF is a drug-linker conjugate composed of a potent antitubulin agent MMAF and a linker DBM to make antibody drug conjugate (ADC).

DBCO-PEG4-Val-Cit-PAB-MMAF is a chemical compound consisting of a cleavable 4 unit polyethylene glycol antibody-drug conjugate (ADC) linker (DBCO-PEG4-Val-Cit-PAB) and a potent inhibitor of tubulin polymerization (MMAF). This compound is an essential component in the synthesis of ADCs.

DBCO-PEG4-MMAF is an antibody-drug conjugate (ADC) component that exhibits potent antitumor activity. It combines the tubulin polymerization inhibitor MMAF with a cleavable linker, DBCO-PEG4, to target cancer cells effectively.

OncoFAP-GlyPro-MMAF is a Drug-Linker Conjugate for ADC (antibody-drug conjugate) that exhibits potent antitumor activity. It is composed of Monomethylauristatin F and a linker, and is utilized in the synthesis of ADCs.

DBCO-PEG4-VC-PAB-MMAF is a click-reactive Drug-linker that contains a DBCO group and can undergo a strain-promoted acetylene-nitride cycloaddition reaction (SPAAC) with molecules containing an Azide group. MMAF is an effective inhibitor of microtubulin polymerization. DBCO-PEG4-VC-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs).

Gly-Gly-Gly-MMAF is a transpeptidase reaction-type Drug-linker, featuring an innovative highly stable and degradable linker. MMAF is an effective tubulin polymerization inhibitor, commonly used in the synthesis of antibody-drug conjugates (ADCs).

DBCO-PEG3-Glu-VC-PABC-MMAF (compound s19b) is a cleavable ADC linker of the PEG class, used in the synthesis of antibody-drug conjugates (ADCs).

Modified MMAF, a cytotoxin for antibody-drug conjugates (ADC), facilitates the synthesis of ADCs tailored for targeted cancer research [1].

Mal-PEG8-Val-Cit-PAB-MMAF, a drug-linker conjugate utilized for antibody-drug conjugates (ADCs), includes a cleavable linker system and the potent tubulin inhibitor monomethyl auristatin F (MMAF), designed for targeted cancer therapy.

Val-Cit-PAB-MMAF sodium is an agent-linker conjugate used in antibody-drug conjugates (ADCs), comprising the peptide linker Val-Cit-PAB and the cytotoxic agent monomethyl auristatin F (MMAF), which inhibits tubulin polymerization [1].

Val-Cit-PAB-MMAF is an agent-linker conjugate utilized for antibody-drug conjugates (ADCs), consisting of the peptide linker Val-Cit-PAB and the potent tubulin polymerization inhibitor known as MMAF [1].

N3-PEG3-VC-PAB-MMAF (Comp T-88-5) is a drug-linker conjugate for antibody-drug conjugates (ADCs) comprising the ADC linker N3-PEG3-VC-PAB and the microtubule-disrupting agent MMAF [1]. This click chemistry reagent features an azide group for copper-catalyzed azide-alkyne cycloaddition (CuAAC) with alkyne-bearing molecules and can also perform strain-promoted alkyne-azide cycloaddition (SPAAC) with compounds presenting DBCO or BCN groups.

Fmoc-MMAF-OMe is a tubulin polymerization inhibitor and anticancer agent featuring an Fmoc protecting group. Its active component, MMAF, serves as the cytotoxic (ADC Cytotoxin) element in conventional antibody-drug conjugates (ADCs) [1].

Amidate-VC-PAB-MMAF, a cleavable ADC linker (Amidate-VC-PAB) combined with a potent tubulin polymerization inhibitor (MMAF), is utilized in the synthesis of antibody-drug conjugates (ADCs) to decrease off-target cytotoxicity[1].

NHS-MMAF is a NHS-modified MMAF that can be used in life science related research. The CAS number of NHS-MMAF is 1404073-19-3.